Research W arfarin therapy is strongly recommended for the prevention of stroke in moderate-and high-risk patients with atrial fibrillation.
Patient decision aids are designed to supplement clinician counselling on treatment options and outcomes so that patients can make specific, informed decisions about their care. [27] [28] [29] [30] It has been reported that they can improve knowledge, reduce decisional conflict and stimulate patients to be more active in decision-making. [31] [32] [33] However, the jury is still out as to their appropriateness for all patients, their cost-effectiveness and their usability in busy clinical practices or when providers disagree with their advice. [31] [32] [33] In addition, it is unknown whether the features of decision instruments in terms of their format and content may influence patient decisions.
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People with atrial fibrillation have been identified as patients who would benefit from a decision aid, since the benefits and harms of the treatment options (including "do nothing") have an important impact on morbidity and mortality. 39, 40 Also, patients have expressed antipathy to anticoagulation with warfarin because the name "warfarin" is associated with rat poison. However, the effect of drug name on knowledge or decisions about therapy is unknown.
We conducted a randomized trial to test (a) whether the format of the decision aid (decision board, decision booklet with audiotape, or interactive computer program) and the graphic presentation of outcome probability data (pie chart or pictogram) would influence patients' comprehension of information about benefits and harms of treatment options, and (b) whether the names of the treatments themselves might influence patients' decisions.
Methods
Information on the anticoagulant treatment options for atrial fibrillation included in the decision aids was based on 3 premises: (a) the potential recipients were 65 years of age or older and had one or more risk factors for stroke; (b) the benefits of the treatment options included in the decision aids were taken from a meta-analysis of 5 randomized controlled trials of anticoagulation; 2 and (c) the probability of a major bleed from warfarin therapy was set between the bleeding rates determined in the meta-analysis and in nonrandomized trials involving outpatients in anticoagulation clinics.
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Identical information was included in each type of decision aid. The information was divided into 3 sections: description of outcomes, treatment choices and probability of outcomes. Outcomes were stroke and major bleeding, each explained in terms of severity and impact. The treatment choices of warfarin, acetylsalicylic acid and no treatmentinitially blinded by labels as "treatment A," "treatment B" and "treatment C" respectively -were described in terms of benefits, harms and impact on lifestyle (e.g., need for monitoring with blood tests with warfarin treatment). Information on the "no treatment" choice was based on data from placebo arms in clinical trials.
All outcomes were characterized as percentages using a 2-year timeline to avoid the need to display fractions. The chance of stroke or major bleeding and the chance of not having either complication were explained as probabilities in the form of pie graphs or pictograms as well as in the text as numbers (e.g., 2 in 100 patients). All descriptions were written at a grade 6 reading level. Reliability and validity of the content were tested beforehand with 8 elderly people who were not part of the subsequent study.
The protocol was approved by the Research Ethics Committee of St. Joseph's Healthcare, Hamilton, Ont. Participants were recruited from 4 family practices and a geriatric day clinical program, all in the Hamilton area. Eligible participants were at least 65 years of age, able to read and understand English and cognitively intact. 44 Patients were excluded from the study if they had received a diagnosis of atrial fibrillation or if they were currently taking warfarin. These eligibility criteria were chosen to select a cohort for which a decision regarding warfarin therapy would be believable but not necessitate a change in their current therapeutic management.
We used a 3 × 2 factorial design to investigate the effects of the following factors on patient comprehension: decision aid format (decision board, decision booklet with audiotape, or interactive computer program) and graphic presentation of the probability data for benefits and harms (pie graph or pictogram). Following informed consent, participants were randomly assigned to receive a decision aid in 1 of the 6 combinations of format type and graphic presentation ( Fig. 1) with the use of a computer-generated randomization sequence. The research assistant conducting the patient interviews was informed of the patient's allocation immediately before the interview.
Participants completed a baseline Atrial Fibrillation Information Questionnaire before receiving the decision aid. This short (10-item) questionnaire comprises true/false statements designed to measure participants' comprehension of atrial fibrillation, treatment options and outcomes. The allocated decision aid was then administered with the treatment options blinded (presented as treatments A, B and C), after which participants were asked to make a treatment choice. The decision aid was administered again, exactly as before, but with the treatment names revealed as "warfarin" (treatment A), "ASA" (acetylsalicylic acid, treatment B) and "no treatment" (treatment C). Participants again were asked to make a treatment choice. They were also asked to provide written reasons for their choices (aided by a checklist), to complete the Atrial Fibrillation Information Questionnaire again, to indicate their satisfaction with the decision instrument on a 6-point scale and to complete the Decisional Conflict Questionnaire. 31 The Decisional Conflict Questionnaire measures perceptions of personal uncertainty in making a treatment choice, with a lower score indicating more comfort with the decision made; scores higher than 2.5 are associated with decisional conflict.
The primary outcome was the change in comprehension, as assessed by the Atrial Fibrillation Information Questionnaire. Possible scores varied from 0 to 10, with a higher score indicating better knowledge. Secondary outcomes were treatment choices before and after unblinding to treatment name, level of satisfaction with the decision aid, and decisional conflict.
We calculated the sample size on the basis of a 2-factor analysis of variance using the primary outcome measure of change in comprehension scores. A difference in scores of 2 (20% change) between any 2 of the 3 methods of presentation was considered by consensus to be the minimal clinically important difference. Assuming a type I error rate of 5%, a type II error rate of 20%, an effect size of 0.40 and a uniform distribution of the 3 means, we calculated a sample size of 27 subjects per decision instrument group. To allow for a 20% dropout rate, we planned to enrol 100 patients.
We used a 2-factor analysis of variance with Tukey's pairwise comparison to evaluate changes in comprehension scores, patient satisfaction scores and decisional conflict scores according to group allocation. Linear and logistic regression were used to evaluate predictors of scores.
Results
Of the 102 patients included in the study, 4 dropped out before their responses could be collected. Our analysis was based on the responses of the remaining 98 patients. The baseline characteristics of the participants are shown in Table  1 . Patients took approximately 60 minutes to complete the questionnaires and the decision aid intervention.
Knowledge of atrial fibrillation improved significantly (p < 0.01) after the decision aid intervention, as indicated by an increase in the mean comprehension score from 4.6 (standard deviation [SD] 2.2) to 7.7 (SD 1.8), regardless of the format or graphic presentation of the decision aid (Table 2) . Age, sex, education level and medical history were not significantly associated with the final comprehension scores or with the change in scores.
While blinded to the treatment names, 39 participants chose treatment A (warfarin), 41 chose treatment B (acetylsalicylic acid), and 18 selected treatment C (no treatment) ( Table  3) . When the decision aid was administered again with the treatment names revealed, the number of participants selecting warfarin decreased to 27 (p = 0.023), the number choosing no treatment decreased to 5 (p < 0.001), and the number selecting acetylsalicylic acid increased to 66 (p < 0.001) ( Table  3 ). The unblinding resulted in 36% of the participants changing their initial treatment choice, including 46% of those who initially chose warfarin and 78% of those who initially chose no treatment. Eighty-eight percent of these switches were to acetylsalicylic acid.
The top 2 reasons participants gave for choosing warfarin (after unblinding) were knowing someone who had had a stroke and fear of stroke. The main reasons given for choosing acetylsalicylic acid were knowing someone who had had a stroke, avoidance of regular blood tests and fear of stroke. The main reasons for choosing no treatment were avoidance of regular blood tests and unwillingness to add a medication. Major bleed 9 (9) Family history of stroke 43 (44) Prefers physician to make drug therapy decisions 28 (29) Note: SD = standard deviation. *Unless stated otherwise. The mean total score on the Decisional Conflict Questionnaire was 2.1 (SD 0.4), which suggests reasonable comfort with the treatment decisions. Factors significantly associated with a higher decisional conflict score were low education level (p < 0.001), low comprehension score at baseline (p < 0.001) and change of treatment choice after unblinding to treatment names (p < 0.05). Ninety-six percent of the participants felt that the information in the decision aids helped them make their treatment decision.
Interpretation
Our elderly participants' knowledge of the treatment benefits and harms associated with anticoagulant therapy for atrial fibrillation significantly improved after receiving the decision aid, and they were highly satisfied with the decision tool's ability to help them with their decision. The format of the decision aid did not matter. For example, there was no evidence of aversion to, or difficulty with, the interactive computer program. The decision booklet plus audiotape, which is likely the most feasible and affordable format for most research and clinical groups, performed equally well. Furthermore, the presentation of numerical data was equally effective, whether by pie chart or pictogram, in improving knowledge scores.
The most remarkable finding of this study was the influence that blinding to treatment names had on patients' stated treatment preferences. Despite identical presentations of information, 36% of the overall group changed their choice when the real treatment names were revealed. This reaction to warfarin, otherwise known to the lay public as rat poison, and to the "no treatment" placebo-arm results speaks to the many seemingly irrational influences on treatment behaviours. These influences may well outweigh strictly evidencebased data or detailed numerical benefit:harm analyses, even if the latter are fully understood. This is an important finding, since some of the participants in our study chose a less effective treatment simply because of its name.
Our study has several limitations. First, we included "surrogate" decision-makers -patients who were in the eligible demographic but were not actually facing the treatment decision. This was done to keep the study feasible in terms of acceptability to treating physicians while maximizing generalizability. Another limitation was the short study period, which prevented long-term follow-up of knowledge gains related to the decision instrument. Finally, although the allocation of the decision aids was random, the component of the study that tested whether the treatment names might influence patients' decisions was a before-after comparison.
Our results help explain the often low uptake of warfarin therapy even among patients for whom the benefits clearly outweigh the harms. The generalizability of these results to treatments other than warfarin or placebo or for treatment goals other than stroke prevention is unknown but worthy of exploration. For clinicians, this study illustrates well the importance of allowing patients time to express their preferences and rationale for treatment options at the time of prescribing, so that treatment compliance can be fully optimized.
Conclusion
We have shown that the use of a patient decision aid, regardless of its format or graphic presentation of data on treatment benefits and harms, significantly improved patients' knowledge of atrial fibrillation and anticoagulant treatment options. Despite demonstrating a high level of comprehension, however, many patients changed their treatment decisions simply in response to learning the true name of the treatment arm. Award from the Canadian Institutes of Health Research. Renée Labiris is a recipient of a Father Sean O'Sullivan Research Centre Career Award.
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